-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
Healthcare AI Shakeout: Health Systems Plan to Cut AI Vendors Nearly in Half by 2028, Black Book Finds
-
Sparta Capital Ltd. Announces Resumption of Trading
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
CORRECTION FROM SOURCE: Nixxy Announces 1-for-20 Reverse Stock Split
-
Olenox Secures Texas Pipeline Operating Permit, Clearing Path for Initial 4 MW Power Deployment
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
Japanese researchers test pioneering drug to regrow teeth
People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.
Unlike reptiles and fish, which usually replace their fangs on a regular basis, it is widely accepted that humans and most other mammals only grow two sets of teeth.
But hidden underneath our gums are the dormant buds of a third generation, according to Katsu Takahashi, head of oral surgery at the Medical Research Institute Kitano Hospital in Osaka.
His team launched clinical trials at Kyoto University Hospital in October, administering an experimental medicine to adult test subjects that they say has the potential to jumpstart the growth of these concealed teeth.
It's a technology "completely new" to the world, Takahashi told AFP.
Prosthetic treatments used for teeth lost to decay, disease or injury are often seen as costly and invasive.
So "restoring natural teeth definitely has its advantages", said Takahashi, the project's lead researcher.
Tests on mice and ferrets suggest that blocking a protein called USAG-1 can awaken the third set, and the researchers have published lab photographs of regrown animal teeth.
In a study published last year, the team said their "antibody treatment in mice is effective for tooth regeneration and can be a breakthrough in treating tooth anomalies in humans".
- 'Only the beginning' -
For now, the dentists are prioritising the "dire" needs of patients with six or more permanent teeth missing from birth.
The hereditary condition is said to affect around 0.1 percent of people, who can have severe trouble chewing, and in Japan often spend most of their adolescence wearing a face mask to hide the wide gaps in their mouth, Takahashi said.
"This drug could be a game-changer for them," he added.
The drug is therefore aimed primarily at children, and the researchers want to make it available as early as 2030.
Angray Kang, a dentistry professor at Queen Mary University of London, only knows of one other team pursuing a similar objective of using antibodies to regrow or repair teeth.
"I would say that the Takahashi group is leading the way," the immunotechnology expert, who is not connected to the Japanese research, told AFP.
Takahashi's work is "exciting and worth pursuing", Kang said, in part because an antibody drug that targets a protein nearly identical to USAG-1 is already being used to treat osteoporosis.
"The race to regenerate human teeth is not a short sprint, but by analogy a set of back-to-back consecutive ultra-marathons," he said.
"This is only the beginning."
Chengfei Zhang, a clinical professor in endodontics at the University of Hong Kong, said Takahashi's method is "innovative and holds potential".
"The assertion that humans possess latent tooth buds capable of producing a third set of teeth is both revolutionary and controversial," he told AFP.
He also cautioned that "outcomes observed in animals do not always directly translate to humans".
The results of the animal experiments raise "questions about whether regenerated teeth could functionally and aesthetically replace missing teeth", Zhang added.
- 'Over the moon' -
A confident Takahashi argues that the location of a new tooth in a mouth can be controlled, if not pinpointed, by the drug injection site.
And if it grows in the wrong place, it can be moved through orthodontics or transplantation, he said.
No young patients with the congenital disorder are taking part in the first clinical trial, as the main objective is to test the drug's safety, rather than its effectiveness.
So for now, the participants are healthy adults who have lost at least one existing tooth.
And while tooth regeneration is not the express goal of the trial this time around, there is a slim chance that it could happen to subjects anyway, Takahashi said.
If so, the researchers will have confirmed that the drug can be effective for those with acquired toothlessness -- which would be a medical triumph.
"I would be over the moon if that happens," Takahashi said.
This could be particularly welcome news in Japan, which has the second-oldest population in the world.
Health ministry data shows more than 90 percent of people aged 75 or older in Japan have at least one tooth missing.
"Expectations are high that our technology can directly extend their healthy life expectancy," Takahashi said.
A.Taylor--AT